Calcium and Nuclear Signaling in Prostate Cancer

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2018 Apr 20

PMID 29671777

Citations 13

Authors

Ivan V Maly

Wilma A Hofmann

Affiliations

Soon will be listed here.

Abstract

Recently, there have been a number of developments in the fields of calcium and nuclear signaling that point to new avenues for a more effective diagnosis and treatment of prostate cancer. An example is the discovery of new classes of molecules involved in calcium-regulated nuclear import and nuclear calcium signaling, from the G protein-coupled receptor (GPCR) and myosin families. This review surveys the new state of the calcium and nuclear signaling fields with the aim of identifying the unifying themes that hold out promise in the context of the problems presented by prostate cancer. Genomic perturbations, kinase cascades, developmental pathways, and channels and transporters are covered, with an emphasis on nuclear transport and functions. Special attention is paid to the molecular mechanisms behind prostate cancer progression to the malignant forms and the unfavorable response to anti-androgen treatment. The survey leads to some new hypotheses that connect heretofore disparate results and may present a translational interest.

Citing Articles

Glyoxalase System in Breast and Ovarian Cancers: Role of MEK/ERK/SMAD1 Pathway.

Alhujaily M Biomolecules. 2024; 14(5).

PMID: 38785990 PMC: 11117840. DOI: 10.3390/biom14050584.

Whole-exome sequencing of Nigerian benign prostatic hyperplasia reveals increased alterations in apoptotic pathways.

White J, Kaninjing E, Adeniji K, Jibrin P, Obafunwa J, Ogo C Prostate. 2024; 84(5):460-472.

PMID: 38192023 PMC: 10922327. DOI: 10.1002/pros.24662.

Orexins and Prostate Cancer: State of the Art and Potential Experimental and Therapeutic Perspectives.

Costagliola A, Lombardi R, Liguori G, Morrione A, Giordano A Cancer Genomics Proteomics. 2023; 20(6suppl):637-645.

PMID: 38035703 PMC: 10687730. DOI: 10.21873/cgp.20412.

Identification of Calcium Channel-Related Gene P2RX2 for Prognosis and Immune Infiltration in Prostate Cancer.

Li Q, Wu B, Daba M, Gao X, Chen B, Song G Dis Markers. 2022; 2022:8058160.

PMID: 36246559 PMC: 9553555. DOI: 10.1155/2022/8058160.

New Insights and Emerging Therapeutic Approaches in Prostate Cancer.

Licitra F, Giovannelli P, Di Donato M, Monaco A, Galasso G, Migliaccio A Front Endocrinol (Lausanne). 2022; 13:840787.

PMID: 35222290 PMC: 8873523. DOI: 10.3389/fendo.2022.840787.

References

Yauch R, Gould S, Scales S, Tang T, Tian H, Ahn C . A paracrine requirement for hedgehog signalling in cancer. Nature. 2008; 455(7211):406-10. DOI: 10.1038/nature07275. View

Gao H, Ouyang X, Banach-Petrosky W, Gerald W, Shen M, Abate-Shen C . Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci U S A. 2006; 103(39):14477-82. PMC: 1599986. DOI: 10.1073/pnas.0606836103. View

Fixemer T, Wissenbach U, Flockerzi V, Bonkhoff H . Expression of the Ca2+-selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression. Oncogene. 2003; 22(49):7858-61. DOI: 10.1038/sj.onc.1206895. View

Bidaux G, Flourakis M, Thebault S, Zholos A, Beck B, Gkika D . Prostate cell differentiation status determines transient receptor potential melastatin member 8 channel subcellular localization and function. J Clin Invest. 2007; 117(6):1647-57. PMC: 1866249. DOI: 10.1172/JCI30168. View

Sagredo A, Sagredo E, Cappelli C, Baez P, Andaur R, Blanco C . TRPM4 regulates Akt/GSK3-β activity and enhances β-catenin signaling and cell proliferation in prostate cancer cells. Mol Oncol. 2017; 12(2):151-165. PMC: 5792731. DOI: 10.1002/1878-0261.12100. View

Chen M, Xu P, Peng X, Chen W, Guzman G, Yang X . The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev. 2006; 20(12):1569-74. PMC: 1482477. DOI: 10.1101/gad.1395006. View

Cisterna B, Necchi D, Prosperi E, Biggiogera M . Small ribosomal subunits associate with nuclear myosin and actin in transit to the nuclear pores. FASEB J. 2006; 20(11):1901-3. DOI: 10.1096/fj.05-5278fje. View

Gray L, Perez-Reyes E, Gomora J, Gamorra J, Haverstick D, Shattock M . The role of voltage gated T-type Ca2+ channel isoforms in mediating "capacitative" Ca2+ entry in cancer cells. Cell Calcium. 2004; 36(6):489-97. DOI: 10.1016/j.ceca.2004.05.001. View

van Noesel M, van Bezouw S, Salomons G, VOUTE P, Pieters R, Baylin S . Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res. 2002; 62(7):2157-61. View

10.

Peckham M . How myosin organization of the actin cytoskeleton contributes to the cancer phenotype. Biochem Soc Trans. 2016; 44(4):1026-34. DOI: 10.1042/BST20160034. View

11.

Orrenius S, Zhivotovsky B, Nicotera P . Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol. 2003; 4(7):552-65. DOI: 10.1038/nrm1150. View

12.

Zattelman L, Regev R, Usaj M, Reinke P, Giese S, Samson A . N-terminal splicing extensions of the human gene fine-tune the kinetics of the three full-length myosin IC isoforms. J Biol Chem. 2017; 292(43):17804-17818. PMC: 5663880. DOI: 10.1074/jbc.M117.794008. View

13.

Bethel C, Faith D, Li X, Guan B, Hicks J, Lan F . Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. Cancer Res. 2006; 66(22):10683-90. DOI: 10.1158/0008-5472.CAN-06-0963. View

14.

Nicotera P, Zhivotovsky B, Orrenius S . Nuclear calcium transport and the role of calcium in apoptosis. Cell Calcium. 1994; 16(4):279-88. DOI: 10.1016/0143-4160(94)90091-4. View

15.

Dzijak R, Yildirim S, Kahle M, Novak P, Hnilicova J, Venit T . Specific nuclear localizing sequence directs two myosin isoforms to the cell nucleus in calmodulin-sensitive manner. PLoS One. 2012; 7(1):e30529. PMC: 3266300. DOI: 10.1371/journal.pone.0030529. View

16.

Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J . Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell. 2003; 4(3):209-21. DOI: 10.1016/s1535-6108(03)00215-0. View

17.

Rios-Doria J, Kuefer R, Ethier S, Day M . Cleavage of beta-catenin by calpain in prostate and mammary tumor cells. Cancer Res. 2004; 64(20):7237-40. DOI: 10.1158/0008-5472.CAN-04-1048. View

18.

Hauser A, Attwood M, Rask-Andersen M, Schioth H, Gloriam D . Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov. 2017; 16(12):829-842. PMC: 6882681. DOI: 10.1038/nrd.2017.178. View

19.

Acevedo V, Gangula R, Freeman K, Li R, Zhang Y, Wang F . Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell. 2007; 12(6):559-71. DOI: 10.1016/j.ccr.2007.11.004. View

20.

Shen M, Abate-Shen C . Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010; 24(18):1967-2000. PMC: 2939361. DOI: 10.1101/gad.1965810. View